NCI Study Targets Barriers to Colorectal Cancer Screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

BETHESDA, Md-National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

BETHESDA, Md—National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

Questionnaires are being sent to a representative sample that includes 1,389 primary care physicians, 1,042 medical specialists, and 323 health plan medical directors. Researchers are seeking data on factors that may affect the use of screening and diagnostic follow-up in community practices. The study aims to assess the knowledge of physicians and their attitudes, practice patterns, and health plan guidelines for providing or promoting colorectal cancer screening.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content